2190 — Zylox-Tonbridge Medical Technology Co Income Statement
0.000.00%
Last trade - 00:00- HK$15.30bn
- HK$13.63bn
- CNY782.48m
Annual income statement for Zylox-Tonbridge Medical Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 27.6 | 178 | 334 | 528 | 782 |
| Cost of Revenue | |||||
| Gross Profit | 16.3 | 132 | 253 | 385 | 560 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 128 | 390 | 542 | 684 | 746 |
| Operating Profit | -100 | -212 | -208 | -157 | 36.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -100 | -200 | -114 | -78.7 | 100 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -100 | -200 | -114 | -78.7 | 100 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -100 | -200 | -114 | -78.7 | 100 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -100 | -200 | -114 | -78.7 | 100 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.302 | -0.601 | -0.315 | -0.238 | 0.331 |
| Dividends per Share |